Reinartz, M. T. and Wetzke, M. and Happle, C. and Kaelble, S. and Scherer, R. and Kabesch, M. and Seifert, R. (2016) Neutrophilic superoxide production can assess pharmacological and pharmacogenetic -adrenoreceptor effects. ALLERGY, 71 (8). pp. 1223-1227. ISSN 0105-4538, 1398-9995
Full text not available from this repository. (Request a copy)Abstract
Asthma can be controlled well in most patients by inhaled -adrenoreceptor ((2)AR) agonists and steroids. Poor response to (2)AR agonists is difficult to predict, especially in young children and by lung function testing, which may be affected by multiple influences. As an alternative approach, we analyzed ex vivo neutrophilic superoxide inhibition in response to (2)AR stimulation. In 60 healthy volunteers, this assay was unaffected by sex, age, smoking, atopy or asthma status. Furthermore, we assessed effects of genetic variants in (2)AR by sequencing the ADRB2 gene in our cohort and relating genotypes to (2)AR-mediated neutrophilic superoxide inhibition. Gly16Arg genotypes correlated with minor decrease in overall adrenoresponse in this small study population. Taken together, ex vivo testing of the (2)AR response in human neutrophils represents a robust tool with good signal-to-noise ratio at physiological (2)AR agonist concentrations, and this assay may be useful to complement future pharmacogenetic studies in asthma.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ASTHMA; POLYMORPHISM; MECHANISMS; RECEPTOR; ADRB2; asthma; neutrophils; SNP; (2)AR agonist |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Kinder- und Jugendmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Mar 2019 10:13 |
| Last Modified: | 22 Mar 2019 10:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3575 |
Actions (login required)
 |
View Item |
